0000000000284992

AUTHOR

Shahrzad Bakhtiar

showing 5 related works from this author

Long-Term Outcome of Preemptive Immunotherapy Based on Post-Transplant Chimerism and MRD Monitoring after Allogeneic Stem Cell Transplantation in Chi…

2014

Abstract Introduction: Mixed chimerism (MC) and minimal residual disease (MRD) strongly predict risk for relapse in children with acute lymphoblastic leukemia (ALL) following allogeneic stem cell transplantation (allo-SCT). Preemptive immunotherapy (IT), e.g. withdrawal of immunosuppression (WD-IS) or donor lymphocyte infusion (DLI) guided by chimerism and MRD monitoring can prevent impending relapse in allo-SCT recipients. In this study we retrospectively analyzed chimerism and MRD monitoring and the effect of preemptive IT in all pts undergoing allo-SCT for ALL in our institution. Patients: Between January 2005 and July 2014, a total of 89 children and adolescents (median age 11.5; range …

Oncologymedicine.medical_specialtybusiness.industryImmunologyCell BiologyHematologyThioTEPASingle Centermedicine.diseaseBiochemistryMinimal residual diseaseDonor lymphocyte infusionFludarabineSurgeryTransplantationhemic and lymphatic diseasesInternal medicineAcute lymphocytic leukemiamedicineCumulative incidencebusinessmedicine.drugBlood
researchProduct

Characterization of the Clinical and Immunologic Phenotype and Management of 157 Individuals with 56 Distinct Heterozygous NFKB1 Mutations

2020

Contains fulltext : 229571.pdf (Publisher’s version ) (Closed access) BACKGROUND: An increasing number of NFKB1 variants are being identified in patients with heterogeneous immunologic phenotypes. OBJECTIVE: To characterize the clinical and cellular phenotype as well as the management of patients with heterozygous NFKB1 mutations. METHODS: In a worldwide collaborative effort, we evaluated 231 individuals harboring 105 distinct heterozygous NFKB1 variants. To provide evidence for pathogenicity, each variant was assessed in silico; in addition, 32 variants were assessed by functional in vitro testing of nuclear factor of kappa light polypeptide gene enhancer in B cells (NF-κB) signaling. RESU…

0301 basic medicineMaleNF-KAPPA-BMedizinlnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]Fluorescent Antibody TechniqueAutoimmunityDiseaseNUCLEAR-FACTORKaplan-Meier Estimatemedicine.disease_causeHypogammaglobulinemia0302 clinical medicineNFKB1 variants and mutations; autosomal dominant inheritance; common variable immunodeficiency; reduced penetrance; variable expressivityHDE PEDImmunology and Allergyvariants and mutationsNF-κB1-related phenotypeImmunodeficiencyIMMUNODEFICIENCY*NF-?B1-related phenotypeNFKB1 variants and mutations1184 Genetics developmental biology physiologycommon variable immunodeficiencyDisease ManagementMiddle AgedNF-kappa B1-related phenotypereduced penetrancePrognosisPenetranceImmunohistochemistryMagnetic Resonance Imaging3. Good healthPhenotypeNFKB1 variant*NFKB1 variant*common variable immunodeficiencyFemaleHaploinsufficiency*reduced penetranceNFKB1 mutationAdultHeterozygote*NFKB1 mutationImmunologyHAPLOINSUFFICIENCYArticle03 medical and health sciencesvariable expressivityautosomal dominantmedicineHumansGenetic Predisposition to DiseaseGenetic Association StudiesAgedbusiness.industryCommon variable immunodeficiencyNF-kappa B p50 SubunitNF-KAPPA-B1Immune dysregulationmedicine.diseaseautosomal dominant inheritance030104 developmental biologyBiological Variation PopulationImmunologyCELLSMutation*autosomal dominantPrimary immunodeficiency3111 BiomedicinebusinessTomography X-Ray ComputedBiomarkers030215 immunology
researchProduct

Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation

2016

Abstract Monitoring of minimal residual disease (MRD) or chimerism may help guide pre-emptive immunotherapy (IT) with a view to preventing relapse in childhood acute lymphoblastic leukemia (ALL) after transplantation. Patients with ALL who consecutively underwent transplantation in Frankfurt/Main, Germany between January 1, 2005 and July 1, 2014 were included in this retrospective study. Chimerism monitoring was performed in all, and MRD assessment was performed in 58 of 89 patients. IT was guided in 19 of 24 patients with mixed chimerism (MC) and MRD and by MRD only in another 4 patients with complete chimerism (CC). The 3-year probabilities of event-free survival (EFS) were .69 ± .06 for …

AdultMaleOncologymedicine.medical_specialtyNeoplasm ResidualAdolescentmedicine.medical_treatmenteducationDiseaseRelapse preventionChimerismYoung Adult03 medical and health sciences0302 clinical medicineRecurrenceGermanyInternal medicineSecondary PreventionHumansTransplantation HomologousMedicineddc:610ChildChildhood Acute Lymphoblastic LeukemiaImmunosuppression TherapyTransplantationbusiness.industryHematopoietic Stem Cell TransplantationRetrospective cohort studyHematologyImmunotherapyPrecursor Cell Lymphoblastic Leukemia-LymphomaSurvival AnalysisMinimal residual diseaseSurgeryTransplantationChild PreschoolLymphocyte Transfusion030220 oncology & carcinogenesisCohortFemaleImmunotherapybusiness030215 immunologyBiology of Blood and Marrow Transplantation
researchProduct

Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience

2016

Therapy for post-transplant relapse of paediatric ALL is limited. Standardised curative approaches are not available. We hereby describe our local procedure in this life-threatening situation. A total of 101 ALL patients received their first allogeneic stem cell transplantation (SCT) in our institution. After relapse, our primary therapeutic goal was to cure the patient with high-dose chemotherapy or specific immunotherapy (HDCHT/SIT) followed by a second SCT from a haploidentical donor (transplant approach). If this was not feasible, low-dose chemotherapy and donor lymphocyte infusions (LDCHT+DLI) were offered (non-transplant approach). A total of 23 patients suffered a post-transplant rel…

Malemedicine.medical_specialtyLymphocyte TransfusionAdolescentmedicine.medical_treatment03 medical and health sciences0302 clinical medicineRecurrenceGermanymedicineHumansProgenitor cellChildRetrospective StudiesTransplantationChemotherapybusiness.industryInfantRetrospective cohort studyHematologyImmunotherapyPrecursor Cell Lymphoblastic Leukemia-LymphomaAllograftsmedicine.diseaseTissue DonorsSurgeryTransplantationClinical trialsurgical procedures operativeGraft-versus-host diseaseChild PreschoolLymphocyte Transfusion030220 oncology & carcinogenesisFemaleImmunotherapybusinessStem Cell Transplantation030215 immunologyBone Marrow Transplantation
researchProduct

A PCR-Based Assay for the Detection of Langerhans-Cell Chimerism after Allogeneic Stem Cell Transplantation.

2006

Abstract Early acute GVHD of the skin frequently occurs in patients after allogeneic hematopoietic stem cell transplantation. Although T cell depletion reduces the incidence and severity, it does not completely prevent skin GVHD. This leads to a prolonged need for immunosuppressive medication in a significant number of patients. For the induction of acute GVHD, the stimulation of donor T cells by residing host antigen presenting cells such as Langerhans cells of the skin (LCs) plays a central role. The absence of donor T cells after depletion, however, seems to hamper an early switch of LCs from host to donor origin. Therefore, the monitoring of LC chimerism is of great interest. We and oth…

Langerhans cellintegumentary systemLangerinbiologymedicine.medical_treatmentT cellImmunologyCell BiologyHematologyHuman leukocyte antigenHematopoietic stem cell transplantationBiochemistryMolecular biologyTransplantationmedicine.anatomical_structureImmunologymedicinebiology.proteinStem cellAntigen-presenting cellBlood
researchProduct